Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease source : Www.biospace.com save search
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
ARWR | $23.285 -2.08% -2.13% 810K
|
Health Technology
|
| O: -0.76%
H: 0.0%
C: 0.0%
disease kidney treatment pharmaceuticals for study
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
DGX | News | $137.55 0.62% 0.0% 1.6M
|
Health Services
|
| O: 0.33%
H: 0.0%
C: 0.0%
disease services biomarker blood risk alzheimer's diagnostics
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
Published: 2024-04-22 (Crawled : 13:00) - biospace.com/
NRSN | News | $1.33 -2.21% -2.26% 130K
|
|
| O: -1.41%
H: 2.86%
C: -3.57%
precision disease ongoing alzheimer's collaboration trial
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio fda disease active for therapy
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $14.0 8.11% 7.5% 2.3M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
OABI | News | $4.56 -1.72% -1.75% 560K
|
|
| O: -1.58%
H: 1.77%
C: -0.4%
drug liver disease antibody for
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
CRL | News | $239.43 -0.29% -5.0% 710K
|
Commercial Services
|
| O: 0.93%
H: 0.36%
C: -0.05%
rare disease collaboration therapeutics therapy
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.73%
H: 2.49%
C: 0.11%
abrysvo disease positive risk for rsv results study
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
vx-147 disease kidney treatment trial
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Published: 2024-03-28 (Crawled : 22:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.26%
H: 2.03%
C: 1.57%
first disease active update trial
Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease
Published: 2024-03-26 (Crawled : 19:00) - biospace.com/
DNLI | $15.55 -3.48% -3.6% 940K
|
Health Technology
|
| O: 1.33%
H: 0.25%
C: -1.27%
disease parkinson's health technology biomarkers
Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
DGX | News | $137.55 0.62% 0.0% 1.6M
|
Health Services
|
| O: 0.26%
H: 0.1%
C: -0.58%
disease test blood alzheimer's imaging study
United States Food & Drug Administration Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease
Published: 2024-03-26 (Crawled : 07:00) - biospace.com/
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 23.18%
H: 0.0%
C: 0.0%
drug disease children food trial submission
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
Published: 2024-03-22 (Crawled : 13:00) - biospace.com/
EQ | $1.8 4.65% 4.44% 110K
|
Health Technology
|
| O: -1.81%
H: 9.74%
C: 3.68%
conference disease
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-21 (Crawled : 21:00) - biospace.com/
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: 0.85%
H: 0.88%
C: 0.02%
vx-407 fda drug disease kidney treatment clearance application
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
Published: 2024-03-20 (Crawled : 14:00) - biospace.com/
LUCD | $0.6865 -5.05% -5.32% 230K
|
|
| O: -0.93%
H: 3.74%
C: 3.74%
PAVM | $1.85 -1.07% -1.08% 19K
|
Health Technology
|
| O: 1.95%
H: 14.83%
C: 5.74%
conference disease week diagnostics
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
ANVS | $12.74 7.24% -2.04% 490K
|
Health Technology
|
| O: 10.43%
H: 34.62%
C: 12.69%
announcement disease alzheimer’s update buntanetap study
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
Published: 2024-03-19 (Crawled : 15:30) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 21.74%
H: 19.29%
C: -3.57%
disease pre-clinical positive treatment alzheimer's therapeutics ht-alz study
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
Published: 2024-03-19 (Crawled : 12:00) - biospace.com/
ENVB | $0.938 4.52% 4.33% 180K
|
Health Technology
|
| O: 54.55%
H: 10.0%
C: -30.0%
disease
FDA Approves First Gene Therapy for Rare Pediatric Disease
Published: 2024-03-18 (Crawled : 23:00) - biospace.com/
PRGO | $31.23 2.43% 0.0% 960K
|
Health Technology
|
| O: 0.33%
H: 0.13%
C: -1.51%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.2%
H: 0.08%
C: -1.14%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: 1.71%
H: 0.36%
C: -2.52%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.81%
H: 0.0%
C: 0.0%
fda rare first disease therapy
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.